<DOC>
	<DOCNO>NCT02788747</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , placebo-controlled study patient stable heart failure reduce ejection fraction ( HFrEF ) evaluate effect multiple subcutaneous injection elamipretide leave ventricular function .</brief_summary>
	<brief_title>The Effect Multiple Injections Elamipretide Various Measures Heart Function Patients With Chronic Heart Failure With Reduced Ejection Fraction</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Willing able provide sign informed consent form ( ICF ) prior participation studyrelated procedure . Age ≥40 &lt; 80 year . A known history chronic ischemic nonischemic cardiomyopathy least 6 month duration time initial diagnosis . Receiving heart failure ( HF ) treatment , include , limited , angiotensin convert enzyme inhibitor ( ACEI ) and/or angiotensin receptor blocker ( ARB ) , evidencebased beta blocker treatment HF . Subjects tolerate ACEI ARB due reduce renal function hypotension eligible . Subjects may receive aldosterone antagonist , requirement study . HF consider stable judgment Investigator AND dose HF treatment stable least 1 month prior Screening Visit . In normal sinus rhythm ( electrocardiogram document ) Screening Day 1 history atrial fibrillation past 12 month No hospitalization relate HF within 1 month prior Screening Visit . Left Ventricular Ejection Fraction ( LVEF ) ≥ 35 % 2D echocardiography Screening . At least 3 viable segment ( hyperenhancement &lt; 25 % ) qualify delay gadoliniumenhanced cardiac MRI examination Screening ( confirm independent core lab ) . Women childbearing potential must agree use 1 follow method birth control date sign ICF two month last dose study medication : Abstinence , maintenance monogamous relationship male partner surgically sterilize vasectomy , barrier method AND either hormonal contraception intrauterine device system . Any contraindication MRI scan LVEDD indexed Body Surface Area &gt; 45 mm/m2 Coronary peripheral revascularization procedure , valvular procedure , OR major surgical procedure within 3 month prior Screening Visit . Acute coronary syndrome , stroke transient ischemic attack ( TIA ) within 3 month prior Screening Visit . Obstructive restrictive cardiomyopathy , infiltrative disease myocardium ( e.g. , amyloid , sarcoid , etc . ) myocarditis , reduction LV function think secondary primarily valvular heart disease , prior cardiac valve surgery know aortic stenosis . The presence anticipate placement pacemaker , implantable cardioverter defibrillator ( ICD ) , cardiac resynchronization therapy ( CRT ) device ensue 6week study period . Presence second degree advance heart block . Uncontrolled hypertension define systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 110 mmHg least two consecutive reading . Presence leave ventricular thrombus , pericardial disease , uncorrected thyroid disease dyskinetic leave ventricular aneurysm . Currently receive treatment chemotherapeutic agent immunosuppressant agent receive prior radiation therapy chest . Liver enzymes ( alanine aminotransferase [ ALT ] AND/OR aspartate aminotransferase [ AST ] ) elevation &gt; 3 time upper limit normal ( ULN ) . Total bilirubin &gt; 1.5 time ULN absence Gilbert 's Syndrome . Bleeding diathesis know blood dyscrasia . Anemia , define hemoglobin &lt; 9 g/dL plan blood transfusion next 6 week . Estimated glomerular filtration rate ( eGFR ) &lt; 30 mL/min , use Modification Diet Renal Disease ( MDRD ) Study equation History hepatitis B , hepatitis C Human Immunodeficiency Virus ( HIV ) infection , diagnosis immunodeficiency . Known active drug alcohol abuse within 1 year Screening Visit . Alcohol abuse define 15 drink men per week 8 woman . Recipient investigational drug , stem cell gene therapy , device OR participation another clinical trial , within 3 month prior Screening Visit . Female subject pregnant , plan become pregnant , lactate . Known allergy gadolinium . Currently receive treatment therapeutic dos anticoagulant . Antiplatelet therapy use prevent cardiovascular disease ( primary prevention ) treat chronic disease ( secondary prevention ) permit . Currently receive treatment sacubitril/valsartan trimetazidine .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>